Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia

Therapeutic Drug Monitoring

Volumn 25, Issue 3, 2003, Pages 287-293

  Mihara, Kazuo ^a   Kondo, Tsuyoshi ^a   Yasui Furukori, Norio ^a   Suzuki, Akihito ^a   Ishida, Masayuki ^a   Ono, Shingo ^a   Kubota, Takahiro ^b   Iga, Tatsuji ^b   Takarada, Yutaka ^c   De Vries, Ronald ^d   Kaneko, Sunao ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c TOYOBO CO LTD   (Japan)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

9 Hydroxyrisperidone; CYP2D6 genotype; Risperidone; Schizophrenia; Steady state plasma concentration

Indexed keywords

CYTOCHROME P450 2D6; PALIPERIDONE; RISPERIDONE;

ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; GENOTYPE; HUMAN; HYDROXYLATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METABOLITE; PRIORITY JOURNAL; SCHIZOPHRENIA; STEADY STATE;

ADULT; ANALYSIS OF VARIANCE; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; ISOXAZOLES; JAPAN; MALE; MIDDLE AGED; PYRIMIDINES; RISPERIDONE; SCHIZOPHRENIA;

EID: 0038103561     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200306000-00006     Document Type: Article

References (28)

1. 2 antagonistic properties. J Pharmacol Exp Ther 1988;244:685-93.
2. Leysen JE, Gommeren W, Eens A, et al. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1998;247:661-70.
3. Claus A, Bollen J, De Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicenter double-blind comparative study. Acta Psychiatr Scand 1992;85:295-305.
4. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
5. Huang ML, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993;54:257-68.
6. Mannens G, Huang ML, Meuldermans W, et al. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 1993;21:1134-41.
7. Scordo GM, Spina E, Facciolà G, et al. Cytochrome P450 2D6 genotype and steady state levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology 1999;147:300-5.
8. Van Beijsterveldt L, Geerts RJF, Leysen JE, et al. Regional brain distribution of risperidone and its active metabolite 9-hydroxyrisperidone in the rat. Psychopharmacology 1994;113:53-62.
9. Bertilsson L, Dahl ML, Dalén P. et al. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002;53:111-22.
10. Heim M, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336:529-32.
11. Steen VM, Andreassen OA, Daly AK, et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995;5:215-23.
12. Johansson I, Oscarson M, Yue QY, et al. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-9.
13. Kubota T, Yamaura Y, Ohkawa N, et al. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 2000;5:31-4.
14. Chida M, Yokoi T, Nemoto N, et al. A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype. Pharmacogenetics 1999;9:287-93.
15. Yokoi T, Kosaka Y, Chida M, et al. A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype. Pharmacogenetics 1996;6:395-401.
16. Johansson I, Lundqvist E, Dahl ML, et al. PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 1996;6:351-5.
17. Tateishi T, Chida M, Ariyoshi N, et al. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther 1999;65:70-5.
18. Nishida Y, Fukuda T, Yamamoto I, et al. CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics 2000;10:567-70.
19. Roh HK, Kim CE, Chung WG, et al. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol 2002;57:671-5.
20. Broly F, Gaedigk A, Heim M, et al. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991;10:545-8.
21. Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 1999;359:147-51.
22. Yasui-Furukori N, Hidestrand M, Spina E, et al. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 2001;29:1263-8.
23. Bork JA, Rogers T, Wedlund PJ, et al. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 1999;60:469-76.
24. Spina E, Avenoso A, Facciolà G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Monit Drug 2000;22:481-5.
25. Ono S, Mihara K, Suzuki A, et al. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology 2002;162:50-4.
26. Pirmohamed M, Allott R, Green VJ, et al. Lymphocyte microsomal epoxide hydrolase in patients on carbamazepine therapy. Br J Clin Pharmacol 1994;37:577-81.
27. Snoeck E, Van Peer A, Sack M, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology 1995;12:223-9.
28. Spina E, Avenoso A, Facciolà G, et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology 2001;153:238-43.